Antibody ID	ANI0HNFHN
Antibody Name	huAb13v1
Antibody Type	Monoclonal antibody (mAb)
Antibody Subtype	Humanized IgG1-kappa
Antigen Name	CD276 antigen (CD276)					Antigen Info

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	35.00%	Positive CD276 expression (CD276 +++/++)
Method Description	Humanized anti-B7-H3 antibodies huAb13v1, huAb3v2.5 and huAb3v2.6 were selected to beconjugated with several Bcl-xL inhibitor payloads and were evaluated in xenograft models of small cell lung cancer (H146). The dose was 6 mg/kg/IP/QDx1.
In Vivo Model	H146 CDX model
In Vitro Model	Small cell carcinoma	NCI-H146 cells		CVCL_1473

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.86 nM	Positive CD276 expression (CD276 +++/++)
Method Description	The anti-tumor activity of these ADCs was tested in cytotoxicity assaysusing the NCI-H1650 non-small cell lung cancer cell line. IC50 values were determined by quantitating viable cells using a CellTiter-Glo luminescent assay.
In Vitro Model	Lung adenocarcinoma	NCI-H1650 cells		CVCL_1483

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	46.00%	Positive CD276 expression (CD276 +++/++)
Method Description	Humanized anti-B7-H3 antibodies huAb13v1 was selected to beconjugated with several Bcl-xL inhibitor payloads and were evaluated in xenograft models of small cell lung cancer (H1650). The dose was 1 mg/kg/IP/QDx1.
In Vivo Model	H1650 CDX model
In Vitro Model	Lung adenocarcinoma	NCI-H1650 cells		CVCL_1483
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	48.00%	Positive CD276 expression (CD276 +++/++)
Method Description	Humanized anti-B7-H3 antibodies huAb13v1 was selected to beconjugated with several Bcl-xL inhibitor payloads and were evaluated in xenograft models of small cell lung cancer (H1650). The dose was 3 mg/kg/IP/QDx1.
In Vivo Model	H1650 CDX model
In Vitro Model	Lung adenocarcinoma	NCI-H1650 cells		CVCL_1483
Experiment 3 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	56.00%	Positive CD276 expression (CD276 +++/++)
Method Description	The anti-tumor activity of huAb13vl as CZ or TX conjugates as purified DAR2 (E2)conjugates were characterized in enograft models of non-small cell lung cancer of human origin. The dose was ADC 3 mg/kg (Q14Dx3/IP).
In Vivo Model	NCI-H1650 CDX model
In Vitro Model	Lung adenocarcinoma	NCI-H1650 cells		CVCL_1483
Experiment 4 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	60.00%	Positive CD276 expression (CD276 +++/++)
Method Description	The anti-tumor activity of huAb13vl as CZ or TX conjugates as purified DAR2 (E2)conjugates were characterized in enograft models of non-small cell lung cancer of human origin. The dose was ADC 1 mg/kg (Q14Dx3/IP).
In Vivo Model	NCI-H1650 CDX model
In Vitro Model	Lung adenocarcinoma	NCI-H1650 cells		CVCL_1483
Experiment 5 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	62.00%	Positive CD276 expression (CD276 +++/++)
Method Description	Humanized anti-B7-H3 antibodies huAb13v1 was selected to beconjugated with several Bcl-xL inhibitor payloads and were evaluated in xenograft models of small cell lung cancer (H1650). The dose was 10 mg/kg/IP/QDx1.
In Vivo Model	H1650 CDX model
In Vitro Model	Lung adenocarcinoma	NCI-H1650 cells		CVCL_1483
Experiment 6 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	67.00%	Positive CD276 expression (CD276 +++/++)
Method Description	The anti-tumor activity of huAb13vl as CZ or TX conjugates as purified DAR2 (E2)conjugates were characterized in enograft models of non-small cell lung cancer of human origin. The dose was ADC 10 mg/kg (Q14Dx3/IP).
In Vivo Model	NCI-H1650 CDX model
In Vitro Model	Lung adenocarcinoma	NCI-H1650 cells		CVCL_1483
Experiment 7 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	88.00%	Positive CD276 expression (CD276 +++/++)
Method Description	The anti-tumor activity of huAb13vl as CZ or TX conjugates as purified DAR2 (E2)conjugates were characterized in enograft models of non-small cell lung cancer of human origin. The dose was ADC 1 mg/kg (Q4Dx6/IP) plus Docetaxel 7.5 mg/kg (Q14Dx3/IV).
In Vivo Model	NCI-H1650 CDX model
In Vitro Model	Lung adenocarcinoma	NCI-H1650 cells		CVCL_1483
Experiment 8 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	98.00%	Positive CD276 expression (CD276 +++/++)
Method Description	The anti-tumor activity of huAb13vl as CZ or TX conjugates as purified DAR2 (E2)conjugates were characterized in enograft models of non-small cell lung cancer of human origin. The dose was ADC 10 mg/kg (Q4Dx6/IP) plus Docetaxel 7.5 mg/kg (Q14Dx3/IV).
In Vivo Model	NCI-H1650 CDX model
In Vitro Model	Lung adenocarcinoma	NCI-H1650 cells		CVCL_1483
Experiment 9 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	99.00%	Positive CD276 expression (CD276 +++/++)
Method Description	The anti-tumor activity of huAb13vl as CZ or TX conjugates as purified DAR2 (E2)conjugates were characterized in enograft models of non-small cell lung cancer of human origin. The dose was ADC 3 mg/kg (Q4Dx6/IP) plus Docetaxel 7.5 mg/kg (Q14Dx3/IV).
In Vivo Model	NCI-H1650 CDX model
In Vitro Model	Lung adenocarcinoma	NCI-H1650 cells		CVCL_1483

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	2.00 nM	Positive CD276 expression (CD276 +++/++)
Method Description	The anti-tumor activity of these ADCs was tested in cytotoxicity assaysusing the H146 small cell lung cancer cell line. IC50 values were determined by quantitating viable cells using a CellTiter-Glo luminescent assay.
In Vitro Model	Small cell carcinoma	NCI-H146 cells		CVCL_1473

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	52.00%	Positive CD276 expression (CD276 +++/++)
Method Description	The anti-tumor activity of huAb13vl as CZ or TX conjugates as purified DAR2 (E2)conjugates were characterized in enograft models of non-small cell lung cancer of human origin. The dose was ADC 10 mg/kg (Q4Dx6/IP).
In Vivo Model	NCI-H1975 CDX model
In Vitro Model	Lung adenocarcinoma	NCI-H1975 cells		CVCL_1511
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	58.00%	Positive CD276 expression (CD276 +++/++)
Method Description	The anti-tumor activity of huAb13vl as CZ or TX conjugates as purified DAR2 (E2)conjugates were characterized in enograft models of non-small cell lung cancer of human origin. The dose was ADC 10 mg/kg (Q4Dx6/IP).
In Vivo Model	EBC-1 CDX model
In Vitro Model	Lung squamous cell carcinoma	EBC-1 cells		CVCL_2891
Experiment 3 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	80.00%	Positive CD276 expression (CD276 +++/++)
Method Description	The anti-tumor activity of huAb13vl as CZ or TX conjugates as purified DAR2 (E2)conjugates were characterized in enograft models of non-small cell lung cancer of human origin. The dose was ADC 10 mg/kg (Q4Dx6/IP).
In Vivo Model	NCI-H1299 CDX model
In Vitro Model	Lung large cell carcinoma	NCI-H1299 cells		CVCL_0060
Experiment 4 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	88.00%	Positive CD276 expression (CD276 +++/++)
Method Description	Humanized anti-B7-H3 antibodies huAb13v1, huAb3v2.5 and huAb3v2.6 were selected to beconjugated with several Bcl-xL inhibitor payloads and were evaluated in xenograft models of small cell lung cancer (H146). The dose was 6 mg/kg/IP/QDx1.
In Vivo Model	H146 CDX model
In Vitro Model	Small cell carcinoma	NCI-H146 cells		CVCL_1473
Experiment 5 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	92.00%	Positive CD276 expression (CD276 +++/++)
Method Description	The anti-tumor activity of huAb13vl as CZ or TX conjugates as purified DAR2 (E2)conjugates were characterized in enograft models of non-small cell lung cancer of human origin. The dose was ADC 10 mg/kg (Q4Dx6/IP) plus Docetaxel 7.5 mg/kg (QDx1/IV).
In Vivo Model	NCI-H1975 CDX model
In Vitro Model	Lung adenocarcinoma	NCI-H1975 cells		CVCL_1511
Experiment 6 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	97.00%	Positive CD276 expression (CD276 +++/++)
Method Description	The anti-tumor activity of huAb13vl as CZ or TX conjugates as purified DAR2 (E2)conjugates were characterized in enograft models of non-small cell lung cancer of human origin. The dose was ADC 10 mg/kg (Q4Dx6/IP) plus Docetaxel 7.5 mg/kg (QDx1/IV).
In Vivo Model	NCI-H1299 CDX model
In Vitro Model	Lung large cell carcinoma	NCI-H1299 cells		CVCL_0060
Experiment 7 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	100.00%	Positive CD276 expression (CD276 +++/++)
Method Description	The anti-tumor activity of huAb13vl as CZ or TX conjugates as purified DAR2 (E2)conjugates were characterized in enograft models of non-small cell lung cancer of human origin. The dose was ADC 10 mg/kg (Q4Dx6/IP) plus Docetaxel 7.5 mg/kg (QDx1/IV).
In Vivo Model	EBC-1 CDX model
In Vitro Model	Lung squamous cell carcinoma	EBC-1 cells		CVCL_2891

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	76.00%	Positive CD276 expression (CD276 +++/++)
Method Description	Humanized anti-B7-H3 antibodies huAb13v1, huAb3v2.5 and huAb3v2.6 were selected to beconjugated with several Bcl-xL inhibitor payloads and were evaluated in xenograft models of small cell lung cancer (H146). The dose was 6 mg/kg/IP/QDx1.
In Vivo Model	H146 CDX model
In Vitro Model	Small cell carcinoma	NCI-H146 cells		CVCL_1473

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.37 nM	Positive CD276 expression (CD276 +++/++)
Method Description	The anti-tumor activity of these ADCs was tested in cytotoxicity assaysusing the NCI-H1650 non-small cell lung cancer cell line. IC50 values were determined by quantitating viable cells using a CellTiter-Glo luminescent assay.
In Vitro Model	Lung adenocarcinoma	NCI-H1650 cells		CVCL_1483

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	80.00%	Positive CD276 expression (CD276 +++/++)
Method Description	The anti-tumor activity of huAb13vl as CZ or TX conjugates as purified DAR2 (E2)conjugates were characterized in enograft models of non-small cell lung cancer of human origin. The dose was ADC 10 mg/kg (QDx1/IP) plus Docetaxel 7.5 mg/kg (QDx1/IV).
In Vivo Model	NCI-H1650 CDX model
In Vitro Model	Lung adenocarcinoma	NCI-H1650 cells		CVCL_1483
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	99.00%	Positive CD276 expression (CD276 +++/++)
Method Description	The anti-tumor activity of huAb13vl as CZ or TX conjugates as purified DAR2 (E2)conjugates were characterized in enograft models of non-small cell lung cancer of human origin. The dose was ADC 10 mg/kg (QDx1/IP) plus Docetaxel 7.5 mg/kg (QDx1/IV).
In Vivo Model	NCI-H1650 CDX model
In Vitro Model	Lung adenocarcinoma	NCI-H1650 cells		CVCL_1483

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.18 nM	Positive CD276 expression (CD276 +++/++)
Method Description	The anti-tumor activity of these ADCs was tested in cytotoxicity assaysusing the NCI-H1650 non-small cell lung cancer cell line. IC50 values were determined by quantitating viable cells using a CellTiter-Glo luminescent assay.
In Vitro Model	Lung adenocarcinoma	NCI-H1650 cells		CVCL_1483

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.21 nM	Positive CD276 expression (CD276 +++/++)
Method Description	The anti-tumor activity of these ADCs was tested in cytotoxicity assaysusing the NCI-H1650 non-small cell lung cancer cell line. IC50 values were determined by quantitating viable cells using a CellTiter-Glo luminescent assay.
In Vitro Model	Lung adenocarcinoma	NCI-H1650 cells		CVCL_1483

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.22 nM	Positive CD276 expression (CD276 +++/++)
Method Description	The anti-tumor activity of these ADCs was tested in cytotoxicity assaysusing the NCI-H1650 non-small cell lung cancer cell line. IC50 values were determined by quantitating viable cells using a CellTiter-Glo luminescent assay.
In Vitro Model	Lung adenocarcinoma	NCI-H1650 cells		CVCL_1483

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.30 nM	Positive CD276 expression (CD276 +++/++)
Method Description	The anti-tumor activity of these ADCs was tested in cytotoxicity assaysusing the NCI-H1650 non-small cell lung cancer cell line. IC50 values were determined by quantitating viable cells using a CellTiter-Glo luminescent assay.
In Vitro Model	Lung adenocarcinoma	NCI-H1650 cells		CVCL_1483

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.33 nM	Positive CD276 expression (CD276 +++/++)
Method Description	The anti-tumor activity of these ADCs was tested in cytotoxicity assaysusing the NCI-H1650 non-small cell lung cancer cell line. IC50 values were determined by quantitating viable cells using a CellTiter-Glo luminescent assay.
In Vitro Model	Lung adenocarcinoma	NCI-H1650 cells		CVCL_1483

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.42 nM	Positive CD276 expression (CD276 +++/++)
Method Description	The anti-tumor activity of these ADCs was tested in cytotoxicity assaysusing the NCI-H1650 non-small cell lung cancer cell line. IC50 values were determined by quantitating viable cells using a CellTiter-Glo luminescent assay.
In Vitro Model	Lung adenocarcinoma	NCI-H1650 cells		CVCL_1483

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.43 nM	Positive CD276 expression (CD276 +++/++)
Method Description	The anti-tumor activity of these ADCs was tested in cytotoxicity assaysusing the NCI-H1650 non-small cell lung cancer cell line. IC50 values were determined by quantitating viable cells using a CellTiter-Glo luminescent assay.
In Vitro Model	Lung adenocarcinoma	NCI-H1650 cells		CVCL_1483

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.45 nM	Positive CD276 expression (CD276 +++/++)
Method Description	The anti-tumor activity of these ADCs was tested in cytotoxicity assaysusing the NCI-H1650 non-small cell lung cancer cell line. IC50 values were determined by quantitating viable cells using a CellTiter-Glo luminescent assay.
In Vitro Model	Lung adenocarcinoma	NCI-H1650 cells		CVCL_1483

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.59 nM	Positive CD276 expression (CD276 +++/++)
Method Description	The anti-tumor activity of these ADCs was tested in cytotoxicity assaysusing the NCI-H1650 non-small cell lung cancer cell line. IC50 values were determined by quantitating viable cells using a CellTiter-Glo luminescent assay.
In Vitro Model	Lung adenocarcinoma	NCI-H1650 cells		CVCL_1483

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.63 nM	Positive CD276 expression (CD276 +++/++)
Method Description	The anti-tumor activity of these ADCs was tested in cytotoxicity assaysusing the NCI-H1650 non-small cell lung cancer cell line. IC50 values were determined by quantitating viable cells using a CellTiter-Glo luminescent assay.
In Vitro Model	Lung adenocarcinoma	NCI-H1650 cells		CVCL_1483

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 133 nM	Positive CD276 expression (CD276 +++/++)
Method Description	The anti-tumor activity of these ADCs was tested in cytotoxicity assaysusing the NCI-H1650 non-small cell lung cancer cell line. IC50 values were determined by quantitating viable cells using a CellTiter-Glo luminescent assay.
In Vitro Model	Lung adenocarcinoma	NCI-H1650 cells		CVCL_1483

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	178.80 nM	Positive CD276 expression (CD276 +++/++)
Method Description	The anti-tumor activity of these ADCs was tested in cytotoxicity assaysusing the NCI-H1650 non-small cell lung cancer cell line. IC50 values were determined by quantitating viable cells using a CellTiter-Glo luminescent assay.
In Vitro Model	Lung adenocarcinoma	NCI-H1650 cells		CVCL_1483

Ref 1	Anti-b7-h3 antibodies and antibody drug conjugates; 2018-03-08.